Iklida's deuterated analogues

By designing deuterated analogs by introducing deuterium atoms at specific sites in ectena, the issues of its physicochemical properties and metabolic stability were resolved, resulting in higher therapeutic levels and less toxicity, and optimizing the in vivo metabolic stability of ectena.

CN111867577BActive Publication Date: 2026-11-17IZUMI TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201980019051.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-03-21
Filing Date
2019-03-21
Publication Date
2026-11-17
Estimated Expiration
2039-03-21

AI Technical Summary

Technical Problem

Ekritarash, as a P-gp and BCRP inhibitor, has unfavorable physicochemical properties, such as insolubility in water and high lipophilicity, which leads to limited absorption rate. Furthermore, formulations of its deuterated compounds have not performed well in clinical trials, and its metabolic stability is difficult to optimize.

Method used

The design of deuterated analogues of Eclatide involves introducing deuterium atoms at specific sites to block metabolic degradation, thereby increasing drug concentrations at systemic and CNS levels and reducing toxicity.

Benefits of technology

It significantly increased the therapeutic level of ectelida in the systemic circulation, reduced first-pass metabolism and post-systemic biotransformation, and improved the safety and tolerability of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0002680026790000041
    Figure BDA0002680026790000041
  • Figure HDA0002680026800000011
    Figure HDA0002680026800000011
Patent Text Reader

Abstract

This invention relates to efflux inhibitor compounds, compositions, and methods of use thereof. More specifically, the invention includes deuterated analogues of ectolidarone that possess excellent pharmacokinetic properties, making it now possible to promote the accumulation and distribution of therapeutic agents to effective levels in cells or compartments protected by efflux transporters such as breast cancer resistance protein (BCRP) and P-glycoprotein (P-GP). These transporter-protected compartments include the brain, spinal cord, nerves, cerebrospinal fluid, testes, eyeballs, retina, inner ear, placenta, breast, liver, biliary tract, kidney, intestine, lung, adrenal cortex, endometrium, hematopoietic cells, stem cells, and solid tumors. In other embodiments, the invention includes methods of using the deuterated analogues of the invention.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to deuterated active pharmaceutical ingredients and to efflux inhibitors. Background Technology

[0002] Elacridar, formerly known as GF120918, is a compound with the following structure: 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinyl-carboxamide, or sometimes written as N-4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridinyl-carboxamide. Elacridar was initially described as a selective P-gp inhibitor but is now considered a dual P-gp / BCRP inhibitor. (Matsson P, Pedersen JM, Norinder U, CA and Artursson P, 2009, “Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs”, Pharm Res 26:1816–1831.

[0003] Eclareta has been successfully tested to some extent both in vitro and in vivo as a P-gp and BCRP inhibitor. For example, in cancer patients, co-administration of ecclareta with therapeutics such as paclitaxel (a P-gp substrate) and topotecan (a BCRP substrate) improved oral absorption—presumably by preventing efflux into the intestinal lumen through a P-gp / BCRP pump located in the gastrointestinal (GI) tract. Similarly, in rodents, co-administration of ecclareta with pump substrates such as morphine, amprenavir, imatinib, dasatinib, gefitinib, sorafenib, and sunitinib has been successful to some extent in increasing drug levels in the brain (by blocking P-gp and BCRP-mediated efflux at the blood-brain barrier). An overview of some of these studies can be found in the research report by Sane et al. (Drug Metabolism and Disposition 40:1612–1619, 2012).

[0004] The administration of ectolidar has several limitations. For example, ectolidar has unfavorable physicochemical properties; it is practically insoluble in water, making it difficult to formulate into, for example, injectable or oral dosage forms. Its poor solubility and high lipophilicity result in a limited absorption rate due to dissolution from the intestinal lumen.

[0005] Various methods have been developed to enhance the efficacy of Eclipta prostrata. For example, U.S. Patent Application Publication 20140235631 discloses a nanoparticle formulation to increase oral bioavailability.

[0006] Sane et al. (Journal of Pharmaceutical Sciences, Vol. 102, 1343–1354 (2013)) reported on microemulsion formulations of Eclairida in an attempt to overcome its bioavailability limitations due to dissolution rate.

[0007] Sawicki et al. (Drug Development and Industrial Pharmacy, 2017, Vol. 43, No. 4, 584–594) described a lyophilized amorphous solid dispersion formulation of ectidone hydrochloride-povidone K30-sodium dodecyl sulfate. However, when tested in healthy human volunteers, extremely high doses (e.g., 1000 mg) were required to achieve a Cmax of 326 ng / ml. (Sawicki et al., Drug Delivery and Translation Research, published online November 18, 2016).

[0008] Montesinos et al. (Molecular Pharmaceutics, 2 November 2015; 12(11):3829-38) experimented with several PEGylated liposome formulations of Eclipta, which partially increased the half-life but did not increase efficacy when co-administered with therapeutic agents.

[0009] Due to the significant unpredictability in this field and the poor correlation between animal and human data in many cases, the value of this formulation awaits clinical trials.

[0010] After intravenous injection, a small dose 11 Studies of the systemic distribution of ecrida have shown high levels of accumulation in the liver (Bauer et al., J Nucl Med. 2016; 57:1265-1268). This has led some to suggest that systemic levels of ecrida are also largely limited by hepatic clearance.

[0011] A potentially attractive strategy for improving the metabolic stability of some drugs is deuterium modification. In this approach, attempts are made to slow CYP-mediated drug metabolism or reduce the rate of formation of inactive metabolites by replacing one or more hydrogen atoms with deuterium atoms. Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Compared to hydrogen, deuterium forms stronger bonds with carbon. In selected cases, the increased bond strength conferred by deuterium can positively influence the absorption, distribution, metabolism, excretion, and / or toxicity (“ADMET”) properties of a drug, thereby generating the potential to improve drug efficacy, safety, and / or tolerability. Simultaneously, since deuterium is substantially the same size and shape as hydrogen, replacing hydrogen with deuterium is not expected to affect the biochemical potency and selectivity of the drug compared to the original chemical entity containing only hydrogen.

[0012] Over the past 35 years, a very small percentage of approved drugs have reported effects of deuteration substitution on metabolic rates (see, for example, Blake, MI et al., *Journal of Pharmaceutical Sciences*, 1975, 64:367-91; Foster, AB., *Advances in Drug Research*, 1985, 14:1-40 (“Foster”); Kushner, DJ et al., *Can J Physiol Pharmacol*, 1999, 79-88; Fisher, MB et al., *Curr OpinDrug Discov Devel*, 2006, 9:101-09 (“Fisher”)). The results are variable and unpredictable. For some compounds, deuteration does indeed lead to a decrease in in vivo metabolic clearance. For others, no metabolic changes have been observed. Still, some compounds demonstrate increased metabolic clearance. The enormous unpredictability and variability of the deuterium effect have led experts to question or abandon deuterium modification as a viable drug design strategy for inhibiting metabolism (see Foster on page 35 and Fisher on page 101).

[0013] Even when deuterium atoms are incorporated at known metabolic sites, the effect of deuterium modification on the metabolic properties of drugs is unpredictable. It is only by actually preparing and testing deuterated drugs that one can determine whether the metabolic rate differs from that of their undeuterated counterparts and, where the differences lie. See, for example, Fukuto et al. (J. Med. Chem. 1991, 34, 2871-76). Many drugs have multiple sites at which metabolism is possible. For each drug, the number of sites requiring deuterium substitution and the degree of deuteration necessary to observe any effect on metabolism will be different.

[0014] Given the challenging physicochemical and ADMET properties of ectolida in humans, despite recent advances in formulation, there remains a need in the field for ectolida analogs that can achieve higher and less variable levels in systemic circulation, at the blood-brain barrier, and elsewhere to optimize efflux inhibition. Summary of the Invention

[0015] This invention provides deuterated analogues of Ekritar. In one embodiment, the deuterated analogue of this invention comprises Ekritar, which includes one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more deuterium atoms substituted with hydrogen atoms, wherein the substitutions are collectively located as... Figure 1The deuterium substitutions are located at one or more of positions 2-4, 7-19, 23-39, and 41-43 as specified in the original text. In other embodiments, the analogues of the present invention comprise 1-4 deuterium substitutions, wherein, in addition to one or more deuterium substitutions at one or more of positions 2-4, 7-19, 23-39, and 41-43, the substitutions are collectively located at one or more of positions 5 and 6. The present invention also includes compositions comprising the analogues of the present invention and methods of using them.

[0016] Various deuterated analogues of Ekrita according to the present invention are represented by Formula 1:

[0017]

[0018] Or a pharmaceutically acceptable salt thereof, said analogue comprising at least one deuterium atom, wherein:

[0019] Each Y and each W is independently selected from either hydrogen or deuterium; and

[0020] Each R is independently selected from CH3, CH2D1, CH1D2, and CD3.

[0021] The condition is that if every Y is H and every R is CH3, then at least one W is H. For the convenience of the reader, this condition will be referred to as condition A in this paper. Attached Figure Description

[0022] Figure 1 The image shows Ikrita with a position number.

[0023] Figure 2 A representative method for the synthesis of ecrida is shown. Figure 2 Subdivided into marked as Figure 2A-2D The four pictures.

[0024] Figure 3 The reactant compounds used in the synthesis of ecridia and ecridia analogues are shown. Position numbering reference. Figure 1 The final eclida product shown.

[0025] Figure 4 A representative method for the first step in synthesizing EE60 is shown.

[0026] Figure 5 A representative method for the final step in synthesizing EE60 is shown.

[0027] Figure 6 A representative method for synthesizing EE59 is shown.

[0028] Figure 7 yes Figure 2 Copying; Figure 7 It shows the result of Figure 2The partial view forms the whole and indicates the location of the shown features. Figure 7 A smaller scale view. Detailed Implementation

[0029] As used herein, the following definitions and abbreviations apply.

[0030] “AUC” or “AUC 0-” ∞ "It is the area under the curve extrapolated from time 0 to infinity."

[0031] The term "co-administered" (or "co-therapy" or "in combination with") of analogues or compositions of the present invention with one or more therapeutic agents means administering such analogues or compositions in a single dosage form, simultaneously in separate dosage forms, or in separate dosage forms and at different times. Optionally, co-administration may be provided in any manner that results in the co-occurrence of a second therapeutic agent and an ectalis analogue in the subject.

[0032] "DMF" stands for N,N-dimethylformamide.

[0033] As used in this article, “deuterium atoms substituted” or “deuterium atoms are substituted” refers to deuterium atoms that are substituted by hydrogen atoms.

[0034] "Ecladi" refers to 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acrylamide or N-(4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acrylamide. The term "Ecladi" also refers to compounds containing the same structure described above, except that one or more hydrogen atoms are replaced by deuterium; such compounds are also referred to as deuterated analogs of eccladi or eccladi analogs. Unless the context clearly indicates otherwise, the term "Ecladi" refers to unsubstituted eccladi.

[0035] "One or more Elacridar analog(s)" or "instant analog(s) of the present invention" means the Elacridar analog(s) of the present invention.

[0036] As used herein, "isotope" refers to a species whose chemical structure differs from the specific compound of this invention only in its isotopic composition.

[0037] As used herein, “isotopic enrichment factor” means the ratio of the isotopic abundance in the analogues of the present invention to the natural abundance of a specified isotope (e.g., deuterium).

[0038] As used herein, “isotopic purity” is the percentage of analog molecules in a composition containing a specified number of deuterated atoms at a specified deuteration site.

[0039] As used in this article, “brain Kp” refers to the brain-plasma partition coefficient as measured, as described, for example, in Sane et al., Drug Metabolism and Disposal, Vol. 40, No. 8, 1612-1619.

[0040] When used in relation to analogues of the present invention, "normal valence" refers to the combining power of an element, such as that measured by the number of hydrogen and deuterium atoms it can displace or bond with. For clarity, the normal valence of carbon is 4, the normal valence of oxygen is 2, and the normal valence of nitrogen is 3.

[0041] As used herein, “pharmaceutical acceptable” means, to a reasonable extent of medical judgment, suitable for contact with tissues of humans and other mammals, optionally without excessive toxicity, irritation or immunogenicity, and commensurate with a reasonable benefit / risk ratio.

[0042] "Pharmaceutical acceptable salt" means any nontoxic salt that, when administered to a recipient, can directly or indirectly provide an analogue of the present invention.

[0043] “TBTU” refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetrafluoroborate tetramethylammonium.

[0044] "Unreplaced ecrid" refers to ecrid in which each atom has a natural isotopic abundance.

[0045] Based on the inventors' insights, it has now been discovered that therapeutic levels of ectoda in systemic circulation are significantly inhibited by pre-systemic clearance (also known as first-pass metabolism) in the gastrointestinal (GI) tract and liver, as well as by pre- and post-systemic biotransformation (or elimination). According to the inventors' insights, this biotransformation results in inactive metabolites through specific enzymatic modifications, such as cytochrome monooxygenases and oxidoreductases in the GI tract and liver. Therefore, certain deuterated ectoda analogs have been designed to block metabolic degradation and significantly increase systemic and CNS levels after oral, intravenous, or other routes of administration. According to the inventors' insights, it has also been found that certain ectoda metabolites may be the cause of toxicity. Therefore, the ectoda analogs of the present invention should be safer and exhibit less toxicity.

[0046] Iklida Analog Nomenclature

[0047] For the convenience of readers, Ikrita and Ikrita analogues are for reference only. Figure 1 The structures shown are named accordingly. Each potential deuteration site is assigned a position number. Each ring is assigned a letter. There are two linkers: a formimide linker (linker 1) located between ring C and ring D, and an ethyl linker located between ring D and ring E. For clarity, ring components that are not part of a linker are considered part of the ring. Specific Implementation

[0049] For example, the present invention contemplates each of the exemplary embodiments (“EE”) listed below. Each of the EE is an analogue of the present invention according to the invention. It should be understood that, unless a position is specified, it may be hydrogen or deuterium.

[0050] EE1. Under condition A, an analogue comprising ecridium in which one or more deuterium atoms are substituted (i.e., one or more hydrogen atoms are substituted with corresponding deuterium atoms). Such substitution may be provided in which the normal valence of each atom is maintained.

[0051] EE2. An analogue according to EE1, wherein one, two, three, four, five, six, seven, or eight deuterium atoms are substituted in ring E.

[0052] EE3. The analogues according to EE1 or EE2, wherein one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve deuterium atoms are substituted in ring F.

[0053] EE3.1 An analogue according to any one of EE1 to EE3, wherein one, two or three deuterium atoms are substituted in ring A.

[0054] EE3.2 An analogue according to any one of EE1 to EE3.1, wherein one, two or three deuterium atoms are substituted in the ring C.

[0055] EE3.3 An analogue according to any one of EE1 to EE3.2, wherein one, two, three or four deuterium atoms are substituted in ring D.

[0056] EE3.3 An analogue according to any one of EE1 to EE3.3, wherein one, two or three deuterium atoms are substituted at position 4.

[0057] EE4. An analogue according to any one of EE1 to EE3.3, wherein one or two deuterium atoms are substituted at position 32.

[0058] EE5. An analogue according to any one of EE1 to EE44, wherein two deuterium atoms are substituted at position 32.

[0059] EE6. An analogue according to any one of EE1 to EE5, wherein one or both deuterium atoms are substituted at position 31.

[0060] EE7. An analogue according to any one of EE1 to EE5, wherein two deuterium atoms are substituted at position 31.

[0061] EE8. An analogue according to any one of EE1 to EE7, wherein one or both of the deuterium atoms are substituted at position 29.

[0062] EE9. An analogue according to any one of EE1 to EE7, wherein two deuterium atoms are substituted at position 29.

[0063] EE10. An analogue according to any one of EE1 to EE9, wherein one or both of the deuterium atoms are substituted at position 5.

[0064] EE11. An analogue according to any one of EE1 to EE9, wherein two deuterium atoms are substituted at position 5.

[0065] EE12. An analogue according to any one of EE1 to EE11, wherein one or both of the deuterium atoms are substituted at position 6.

[0066] EE13. An analogue according to any one of EE1 to EE11, wherein two deuterium atoms are substituted at position 6.

[0067] EE14. An analogue according to any one of EE1 to EE11, wherein one, two, or three deuterium atoms are substituted at position 2.

[0068] EE15. An analogue according to any one of EE1 to EE11, wherein three deuterium atoms are substituted at position 2.

[0069] EE16. An analogue according to any one of EE1 to EE15, wherein one, two, or three deuterium atoms are substituted at position 3.

[0070] EE17. An analogue according to any one of EE1 to EE15, wherein three deuterium atoms are substituted at position 3.

[0071] EE18. An analogue according to EE1, wherein two deuterium atoms are substituted at each of positions 5, 6, 29, 31 and 32, and three deuterium atoms are substituted at each of positions 2 and 3.

[0072] EE19. An analogue according to any one of the preceding EE, wherein at the one or more positions containing the substitution, all hydrogen atoms at the one or more positions are substituted with corresponding deuterium atoms.

[0073] EE20. An analogue according to EE1, wherein one, two, or three deuterium atoms are substituted at position 2, and one, two, or three deuterium atoms are substituted at position 3.

[0074] EE21. An analogue according to EE1, wherein three deuterium atoms are substituted at position 2 and three deuterium atoms are substituted at position 3.

[0075] EE22. An analogue according to any one of EE1 and EE20 to EE21, wherein one, two or three deuterium atoms are substituted at position 4.

[0076] EE23. An analogue according to any one of EE1 and EE20 to EE21, wherein three deuterium atoms are substituted at position 4.

[0077] EE24. An analogue according to any one of EE1 and EE20 to EE23, wherein a deuterium atom is substituted at at least one of positions 23, 25, 26 and 28 (i.e., one or more of positions 23, 25, 26 and 28 may contain deuterium substitution).

[0078] EE25. An analogue according to any one of EE1 and EE20 to EE23, wherein a deuterium atom is substituted at each of positions 23 and 25.

[0079] EE26. An analogue according to any one of EE1 and EE20 to EE23, wherein a deuterium atom is substituted at each of positions 26 and 28.

[0080] EE27. An analogue according to any one of EE1 and EE20 to EE23, wherein a deuterium atom is substituted at each of positions 23, 25, 26 and 28.

[0081] EE28. An analogue according to any one of EE1 and EE20 to EE27, wherein one or both of the deuterium atoms are substituted at position 32.

[0082] EE29. An analogue according to any one of EE1 and EE20 to EE27, wherein two deuterium atoms are substituted at position 32.

[0083] EE30. An analogue according to any one of EE1 and EE20 to EE29, wherein one or both deuterium atoms are substituted at positions 31 or 29 or 31 and 29.

[0084] EE31. An analogue according to any one of EE1 and EE20 to EE29, wherein two deuterium atoms are substituted at each of positions 31 and 29.

[0085] EE32. An analogue according to any one of EE1 and EE20 to EE31, wherein a deuterium atom is substituted at one or more of positions 10, 41, 42, 16, 17 and 18.

[0086] EE33. An analogue according to EE1, wherein one to 31 deuterium atoms are substituted at carbon atoms.

[0087] EE34. The analogues according to EE1, wherein one or all of the carbon atoms at positions 2, 3, 5, 6, 10, 16, 17, 18, 23, 25, 26, 28, 29, 31, 32, 41 and 42 are deuterated.

[0088] EE35. The analogues according to EE1 or EE33, comprising at least one of the following:

[0089] i. A deuterium atom substituted at one or more of positions 10, 41, and 42;

[0090] ii. A deuterium atom substituted at one or more of positions 16, 17, and 18;

[0091] iii. A deuterium atom substituted at one or more of positions 23, 25, 26, and 28;

[0092] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0093] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0094] vi. To replace one, two, or three deuterium atoms at one or more positions in positions 2 and 3.

[0095] EE36. The analogues according to EE1 or EE33, comprising at least two of the following:

[0096] i. A deuterium atom substituted at one or more of positions 10, 41, and 42;

[0097] ii. A deuterium atom substituted at one or more of positions 16, 17, and 18;

[0098] iii. A deuterium atom substituted at one or more of positions 23, 25, 26, and 28;

[0099] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0100] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0101] vi. To replace one, two, or three deuterium atoms at one or more positions in positions 2 and 3.

[0102] EE37. The analogues according to EE1 or EE33, comprising at least three of the following:

[0103] i. A deuterium atom substituted at one or more of positions 10, 41, and 42;

[0104] ii. A deuterium atom substituted at one or more of positions 16, 17, and 18;

[0105] iii. A deuterium atom substituted at one or more of positions 23, 25, 26, and 28;

[0106] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0107] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0108] vi. To replace one, two, or three deuterium atoms at one or more positions in positions 2 and 3.

[0109] EE38. The analogues according to EE1 or EE33, comprising at least four of the following:

[0110] i. A deuterium atom substituted at one or more of positions 10, 41, and 42;

[0111] ii. A deuterium atom substituted at one or more of positions 16, 17, and 18;

[0112] iii. A deuterium atom substituted at one or more of positions 23, 25, 26, and 28;

[0113] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0114] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0115] vi. To replace one, two, or three deuterium atoms at one or more positions in positions 2 and 3.

[0116] EE39. The analogues according to EE1 or EE33, comprising:

[0117] i. A deuterium atom substituted at one or more of positions 10, 41, and 42;

[0118] ii. A deuterium atom substituted at one or more of positions 16, 17, and 18;

[0119] iii. A deuterium atom substituted at one or more of positions 23, 25, 26, and 28;

[0120] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0121] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0122] vi. To replace one, two, or three deuterium atoms at one or more positions in positions 2 and 3.

[0123] EE40. The like according to EE1 or EE33, comprising:

[0124] i. A deuterium atom substituted at two or more positions in positions 10, 41 and 42 (i.e., each of the two positions contains a substitution);

[0125] ii. A deuterium atom substituted at two or more positions in positions 16, 17, and 18;

[0126] iii. A deuterium atom substituted at two or more positions in positions 23, 25, 26, and 28;

[0127] iv. Substitution of one or two deuterium atoms at one or more of positions 29, 31, and 32;

[0128] v. to substitute one or two deuterium atoms at one or more positions in positions 5 and 6; and

[0129] vi. To replace one, two, or three deuterium atoms at each of positions 2 and 3.

[0130] EE41. The like according to EE1 or EE33, comprising:

[0131] i. A deuterium atom is substituted at each of positions 10, 41, and 42;

[0132] ii. A deuterium atom is substituted at each of positions 16, 17, and 18;

[0133] iii. A deuterium atom substituted at three or more positions in positions 23, 25, 26, and 28;

[0134] iv. Substitution of one or two deuterium atoms at two or more positions in positions 29, 31 and 32;

[0135] v. to replace one or two deuterium atoms at each of positions 5 and 6; and

[0136] vi. To replace one, two, or three deuterium atoms at each of positions 2 and 3.

[0137] EE42. The like according to EE1 or EE33, comprising:

[0138] i. A deuterium atom is substituted at each of positions 10, 41, and 42;

[0139] ii. A deuterium atom is substituted at each of positions 16, 17, and 18;

[0140] iii. A deuterium atom substituted at each of positions 23, 25, 26, and 28;

[0141] iv. Substitution of one or two deuterium atoms at each of positions 29, 31, and 32;

[0142] v. to replace one or two deuterium atoms at each of positions 5 and 6; and

[0143] vi. To replace one, two, or three deuterium atoms at each of positions 2 and 3.

[0144] EE45. The like according to EE1 or EE33, comprising:

[0145] i. A deuterium atom is substituted at each of positions 10, 41, and 42;

[0146] ii. A deuterium atom is substituted at each of positions 16, 17, and 18;

[0147] iii. A deuterium atom substituted at each of positions 23, 25, 26, and 28;

[0148] iv. The two deuterium atoms substituted at each of positions 29, 31, and 32;

[0149] v. to replace two deuterium atoms at each of positions 5 and 6; and

[0150] vi. To replace two or three deuterium atoms at each of positions 2 and 3.

[0151] EE46. The like according to EE1 or EE33, comprising:

[0152] i. A deuterium atom is substituted at each of positions 10, 41, and 42;

[0153] ii. A deuterium atom is substituted at each of positions 16, 17, and 18;

[0154] iii. The two deuterium atoms substituted at each of positions 29, 31, and 32;

[0155] iv. The two deuterium atoms substituted at each of positions 5 and 6; and

[0156] v. To replace three deuterium atoms at each of positions 2 and 3.

[0157] EE47. An analogue according to any one of EE1 to EE46, comprising one, two, or three deuterium atoms substituted at position 4.

[0158] EE48. An analog of Formula 1 comprising at least one deuterium atom, wherein each Y and each W is independently selected from hydrogen or deuterium; and each R is independently selected from CH3, CH2D1, CH1D2 and CD3, provided that A is true.

[0159] The applicant has conducted a series of in vivo and in vitro experiments to elucidate the metabolism of ecdysone by the liver and possibly elsewhere. Further studies have been conducted to investigate the effects of deuteration at different sites on this metabolism. These results, combined with a reasonable design, have allowed the applicant to design subgenera that are significantly stable compared to the unsubstituted parent, based on the applicant's inventive insight. Furthermore, in the inventors' conception, these analogs block the formation of metabolites that are partly responsible for the toxicity of the unsubstituted parent.

[0160] EE49. The analogues according to EE48, wherein Y14 and Y15 are each composed of deuterium, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0161] EE50. An analogue according to EE48, wherein W3 and W4 are each composed of deuterium, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0162] EE51. An analogue according to EE48, wherein each of W1-W4 is composed of deuterium, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0163] EE52. An analogue according to any one of EE48 to EE51, wherein R2 and R3 each consist of CD3, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0164] EE53. An analogue according to any one of EE48 to EE51, wherein R2 and R3 are each composed of CD3, and wherein Y14 and Y15 are each composed of deuterium, and optionally wherein each of the remaining Ys, Ws and Rs does not contain deuterium.

[0165] EE54. An analogue according to any one of EE48 to EE51, wherein Y2 is deuterium, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0166] EE55. An analogue according to any one of EE48 to EE51, wherein Y2 is deuterium, and R2 and R3 are each composed of CD3, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0167] EE56. An analogue according to any one of EE48 to EE51, wherein R1 is CD3, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0168] EE57. An analogue according to any one of EE48 to EE51, wherein Y9 and Y18 are each composed of deuterium, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0169] EE58. An analogue according to any one of EE48 to EE51, wherein Y2, Y9, Y18 and W1-W4 are each composed of deuterium, and R1-R3 are each composed of CD3, and optionally each of the remaining Ys, Ws and Rs does not contain deuterium.

[0170] EE59. The analogues according to EE48, wherein R1, R2 and R3 are each composed of CD3, and W14 and Y15 are each composed of deuterium, and wherein each of the remaining Ys, Ws and Rs does not contain deuterium.

[0171] EE60. An analogue according to EE48, wherein each Y except Y7 and Y20 is composed of CD3, and each W is composed of deuterium, and R1-R3 are each composed of CD3.

[0172] EE61. An analogue according to any one of the preceding EE analogues, wherein the analogue exists with an isotopic purity of greater than 50%.

[0173] EE62. An analogue according to any one of the preceding EE analogues, wherein the analogue exists with an isotopic purity of greater than 70%.

[0174] EE63. An analogue according to any one of the preceding EE analogues, wherein the analogue exists with an isotopic purity of greater than 90%.

[0175] EE64. An analogue according to any one of the preceding EE analogues, wherein, compared with unsubstituted ecstasy, the human in vivo plasma half-life, in vitro half-life, and AUC 0- ∞ And one or more of Cmax are extended by at least 20%.

[0176] EE65. An analogue according to any one of the preceding EE analogues, wherein, compared with unsubstituted ecstasy, the human in vivo plasma half-life, in vitro half-life, and AUC 0- ∞ And one or more of Cmax are extended by at least 40%.

[0177] EE66. An analogue according to any one of the foregoing EE analogues, wherein, when compared with unsubstituted ecstasy, the human plasma half-life, in vitro half-life, and AUC 0- at the time of administration are... ∞ And one or more of Cmax are extended by at least 40%.

[0178] EE67. The analogue according to any one of the preceding EE analogues, wherein, compared with unsubstituted ecstasy, the human in vivo plasma half-life, in vitro half-life, and AUC 0- ∞ And one or more of Cmax are extended by at least 60%.

[0179] EE68. An analogue according to any one of the preceding EE analogues, wherein, compared with unsubstituted ecstasy, the human in vivo plasma half-life, in vitro half-life, and AUC 0- ∞ And one or more of Cmax are extended by at least 100%.

[0180] EE69. A composition comprising an analogue according to any one of the preceding EE analogues, the composition further comprising a therapeutic agent.

[0181] EE70. The composition according to EE69, wherein the therapeutic agent is selected from the group consisting of: paclitaxel, topotecan, dasatinib, gefitinib, imatinib, pazopanib, sorafenib, sunitinib, vandetanib, erlotinib, crizotinib, docetaxel, doxorubicin, imidazotetrazine, ispinax, paclitaxel, tazemetostat, temozolomide, topotecan, vinca alkaloids, anthracyclines, taxol, paclitaxel derivatives, podophyllotoxin, mitoxantrone, actinomycin, colchicine, gramicidin D, acridine, abacavir, ampravir, lamivudine, ritonavir, zidovudine, loperamide, morphine, n-desmethylloperamide, and pazopanib.

[0182] EE71. An analogue according to any one of EE1 to EE68, wherein when administered orally in at least one human, rat, or mouse at a dose level of at least 1 mg / kg, 5 mg / kg, or 10 mg / kg and co-administered orally with a therapeutic agent according to EE78 at a dose level of 20 mg / kg, the administration causes an increase of at least 20% in brain Kp of the therapeutic agent.

[0183] EE72. An analogue according to any one of EE1 to EE68, wherein when administered orally in at least one human, rat, or mouse at a dose level of at least 1 mg / kg, 5 mg / kg, or 10 mg / kg and co-administered orally with erlotinib at 20 mg / kg, said administration causes an increase of at least 20% in brain Kp of erlotinib.

[0184] Deuteration designation and enrichment and chemical nomenclature

[0185] Unless otherwise specified, when a position is specifically designated as “D” or “deuterium”, the position shall be understood as having a deuterium abundance of at least 3,000 times greater than the natural abundance of deuterium, wherein the natural abundance of deuterium is 0.015% (i.e., at least 45% deuterium incorporation).

[0186] The analogues of the invention taught herein will inherently contain a small amount of isotopes (e.g., isotopes that are present at their natural isotopic abundance at positions other than the substituted positions taught herein).

[0187] In other embodiments, the compounds of the present invention have an isotopic enrichment factor for each specified deuterium atom of at least 3500 (52.5% deuterium doping at each specified deuterium atom), at least 4000 (60% deuterium doping), at least 4500 (67.5% deuterium doping), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium doping), at least 6000 (90% deuterium doping), at least 6333.3 (95% deuterium doping), at least 6466.7 (97% deuterium doping), at least 6600 (99% deuterium doping), or at least 6633.3 (99.5% deuterium doping).

[0188] In analogues of the invention, any atom not specifically designated as a particular isotope is intended to represent any stable isotope of said atom. Unless otherwise stated, when a position is specifically designated as "H" or "hydrogen", said position should be understood to have hydrogen according to its natural abundance isotopic composition.

[0189] The compositions of the present invention may optionally be a collection of molecules having the same chemical structure, except that isotopic variations may exist between the constituent atoms of the molecules. Therefore, it will be apparent to those skilled in the art that compounds represented by a specific chemical structure containing an indicated deuterium atom will also contain a smaller amount of isotopes having hydrogen atoms at one or more designated deuterium positions in said structure. The relative amount of such isotopes in the compounds of the present invention will depend on many factors, including the isotopic purity of the deuterating agent used to prepare the compound and the efficiency of deuterium incorporation in the various synthetic steps used to prepare the compound. However, as mentioned above, the overall relative amount of such isotopes will be less than 55% of the compound. In other embodiments, the overall relative amount of such isotopes will be less than 50%, less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compound.

[0190] Unless otherwise stated, when a disclosed compound is named or described by structure without specifying stereochemistry and has one or more chiral centers, it should be understood that it represents all possible stereoisomers of the compound.

[0191] The analogues of the present invention may contain asymmetric carbon atoms, for example, due to deuterium substitution or other reasons. Thus, the analogues of the present invention can exist as a single enantiomer or a mixture of two enantiomers. Therefore, the compounds of the present invention can exist as racemic mixtures or scalemic mixtures, or as a corresponding single stereoisomer substantially free of another possible stereoisomer. As used herein, the term "substantially free of other stereoisomers" means the presence of less than 25% of other stereoisomers, preferably less than 10% of other stereoisomers, more preferably less than 5% of other stereoisomers, and most preferably less than 2% of other stereoisomers. Methods for obtaining or synthesizing single enantiomers of a given compound are known in the art and can be applied as appropriate to the final analogues or starting materials or intermediates.

[0192] Ekrita Synthesis

[0193] Ecridar can be synthesized as described in U.S. Patent 6,248,891. Those skilled in the art will now readily recognize that the deuterated analogues of the present invention can be prepared by starting with a starting compound deuterated at the appropriate location.

[0194] Another useful method for synthesizing analogues of the present invention generally follows The method of et al. (Journal of Medicinal Chemistry, 8 October 2009; 52(19):6073–6082) in which the reactants are synthesized by appropriate deuteration substitution.

[0195] Bernd et al. described another useful synthetic method (“Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar as a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood-Brain Barrier”, Journal of Medicinal Chemistry 52.19(2009):6073-6082. PMC.Web. March 6, 2018).

[0196] Another useful method for synthesizing analogues of the present invention generally follows Figure 2 The method shown. Figure 3 The order of the reactants (e.g., compounds 1, 2, 5, and 6) shown is based on Figure 1 The final ecridium analogues shown are numbered according to their positions in ecridium. This method is further described in detail in Example 1 by way of example. Using this method, any ecridium analogues taught herein can be synthesized by selecting appropriately deuterated compounds 1, 2, 5, and 6. To aid in the selection of appropriate deuterated reactants, the atoms in the reactants are numbered according to their position numbers in ecridium (showing their positions in the final synthetic product).

[0197] Deuterium can also be selectively or non-selectively incorporated into various sites using proton-deuterium exchange methods known in the art.

[0198] medicinal salt

[0199] The analogues and compositions of the present invention can be prepared as pharmaceutically acceptable salts.

[0200] Acids commonly used to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and phosphoric acid, as well as organic acids such as p-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid, as well as related inorganic and organic acids. Therefore, pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caprates, heptanoates, propiolates, oxalates, and malonates. Succinate, octanoate, sebacic acid, fumarate, maleate, butyn-1,4-diacidate, hexyn-1,6-diacidate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and other salts. In one embodiment, pharmaceutically acceptable acid addition salts comprise acid addition salts formed with inorganic acids (such as hydrochloric acid and hydrobromic acid), and especially with organic acids (such as maleic acid).

[0201] Pharmaceutically acceptable salts may also be salts of the compounds of this invention with a base. Exemplary bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia and organic amines such as unsubstituted or hydroxylated monoalkylamines, dialkylamines, or trialkylamines; dicyclohexylamine; tributylamine; pyridine; N-methylamine; N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tri-(2-OH-(C1-C6)-alkylamines), such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucosamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, etc.

[0202] Compositions, dosage forms and carriers

[0203] The present invention also provides pharmaceutical compositions comprising an effective amount of the compound of the present invention (e.g., an analogue of the present invention) and a pharmaceutically acceptable carrier. One or more carriers are also acceptable in the sense of compatibility with other components of the formulation.

[0204] Pharmaceutically acceptable carriers, adjuvants, and mediators that can be used in the pharmaceutical compositions of the present invention include, but are not limited to: ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffering substances (such as phosphates), glycine, sorbic acid, potassium sorbate, mixtures of saturated vegetable fatty acid metaglycerides, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin. If desired, the solubility and bioavailability of the analogues of the present invention in pharmaceutical compositions can be enhanced by methods well known in the art. One method involves using lipid excipients in the formulation. See “Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs” (Drugs and the Pharmaceutical Sciences), edited by David J. Hauss, Informa Healthcare, 2007; and “Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples”, edited by Kishor M. Wasan, Wiley-Interscience, 2006.

[0205] Optionally, the compositions of the present invention are in solid or liquid form. For example, solid forms comprise tablets or capsules containing granules formulated for oral administration. As another example, liquid forms comprise suspensions or emulsions, such as those comprising emulsifiers or surfactants, such as polysorbate or hydroxypropyl methylcellulose (Sane R, Agarwal S, Elmquist WF, Brain Distribution and Bioavailability of Elacridar after Different Routes of Administration in the Mouse, Drug Metabolism and Disposal 2012; 40(8):1612-1619. doi:10.1124 / dmd.112.045930).

[0206] Optionally, the compositions of the present invention comprise from about 10 mg to about 20,000 mg of an ectilida analogue, for example from about 25 mg to about 1,000 mg. Other contemplated compositions are those that provide the dosage as taught herein.

[0207] Optionally, the compositions of the invention are provided in a container. For example, the container may be a sealed container, a syringe (e.g., configured for IV administration), an IV bag (e.g., for mixing with a chemotherapeutic agent), a vial configured for pills (e.g., having a childproof cap), or a vial configured for liquid preparations (e.g., having a sealing cap configured for puncture by a syringe).

[0208] Optionally, the compositions of the present invention are liquid compositions provided in containers other than analytical containers (e.g., other than NMR tubes or cuvettes).

[0209] In one embodiment, the composition of the present invention comprises an ectoda analogue and a second therapeutic agent, such as any second therapeutic agent taught herein for co-administration with an ectoda analogue.

[0210] In one embodiment, the composition of the invention is configured for any of the administration methods taught herein.

[0211] Application route

[0212] With the teachings of this document, those skilled in the art will readily recognize the ways in which the analogues and compositions of the present invention are applied.

[0213] The pharmaceutical compositions of the present invention comprise pharmaceutical compositions suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, and intradermal) administration. In some embodiments, ectelida analogues are administered transdermally (e.g., using transdermal patches or iontophoresis). Other formulations can be readily presented in unit dosage forms, such as tablets, extended-release capsules, and in liposomes, and can be prepared by any method well known in the pharmaceutical field. See, for example, *Remington: The Science and Practice of Pharmacy*, Lippincott Williams & Wilkins, Baltimore, Md. (20th edition, 2000).

[0214] In some embodiments, the composition is administered orally. Compositions of the invention suitable for oral administration can be available in discrete units, such as capsules, sachets, or tablets each containing a predetermined amount of the active ingredient; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; oil-in-water liquid emulsions; water-in-oil liquid emulsions; filled liposomes; or as pellets, etc. Soft gelatin capsules can be used to contain such suspensions, which can advantageously improve the absorption rate of the compound.

[0215] In the case of tablets for oral administration, common carriers include lactose and corn starch. Lubricants such as magnesium stearate may also be added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When oral administration of aqueous suspensions, the active ingredient is optionally combined with emulsifiers and suspending agents. If desired, certain sweeteners and / or flavoring agents and / or coloring agents may be added.

[0216] Compositions suitable for oral administration include sugar tablets containing the ingredients in a flavoring matrix (typically sucrose and gum arabic or astragalus gum); and soft tablets containing the active ingredients in an inert matrix, such as gelatin and glycerin, or sucrose and gum arabic.

[0217] Compositions suitable for parenteral administration include: aqueous and non-aqueous sterile injectable solutions, which may contain antioxidants, buffers, antibacterial agents, and solutes that provide a formulation isotonic with the intended recipient's blood; and aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickeners. The formulations may be present in single-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored under lyophilized (freeze-dried) conditions where a sterile liquid carrier (e.g., water for injection) needs to be added immediately before use. Temporary injectable solutions and suspensions can be prepared from sterile powders, granules, and tablets.

[0218] This injectable solution can be in the form of, for example, a sterile injectable aqueous or oily suspension. This suspension can be formulated using suitable dispersants or wetting agents (e.g., Tween 80) and suspending agents according to techniques known in the art. The sterile injectable formulation can also be a sterile injectable solution or suspension in a non-toxic, parenteral-acceptable diluent or solvent, such as a solution in 1,3-butanediol. Acceptable mediators and solvents that can be used include mannitol, water, Ringer's solution, and isotonic sodium chloride solution. Additionally, sterile, non-volatile oils are routinely used as solvents or suspension media. For this purpose, any mild, non-volatile oil containing synthetic monoglycerides or diglycerides can be used. Fatty acids such as oleic acid and their glycerol derivatives can be used to prepare injectables, as can natural, pharmaceutically acceptable oils (such as olive oil or castor oil), especially their polyoxyethyleneized forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.

[0219] For rectal administration, the pharmaceutical compositions of the present invention can be administered in the form of suppositories. These compositions can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients that are solid at room temperature but liquid at rectal temperatures, and thus melt in the rectum to release the active ingredient. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol.

[0220] The pharmaceutical compositions of the present invention can be administered via nasal aerosol or inhaler. Such compositions are prepared according to techniques well known in the field of pharmaceutical formulation and can be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers for improving bioavailability, fluorocarbons, and / or other solubilizers or dispersants known in the art. See, for example, Rabinowitz JD and Zaffaroni AC, U.S. Patent No. 6,803,031, assigned to Alexza Molecular Delivery Corporation.

[0221] Topical application of the pharmaceutical compositions of the present invention is particularly useful when the desired treatment involves an area or organ easily accessible by topical application. For topical application to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing an active ingredient suspended or dissolved in a carrier. Carriers for topical application of analogues of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compounds, emulsified waxes, and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing an active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, hexadecyl ester wax, cetearyl alcohol, 2-octyldodecyl alcohol, benzyl alcohol, and water. The pharmaceutical compositions of the present invention can also be applied topically to the lower intestine by rectal suppository formulations or by suitable enema formulations. Topical transdermal patches and iontophoresis are also included in the present invention.

[0222] The application of the ecrida analogue of the present invention can be localized for administration at the site of interest. Various techniques can be used to deliver the subject composition at the site of interest, such as injection, using catheters, cannulas, projectiles, pluronic gels, stents, sustained-release polymers, or other devices for internal access.

[0223] Dosage

[0224] Eclareda analogues can be provided in specific doses. Dosage depends (among other things) on the route of administration. Using standard methods, a technician can easily determine the dosage based on the resulting plasma levels. That said, administration should ensure that plasma C... max Greater than 10 ng / mL, or greater than 20 ng / mL, or greater than 40 ng / mL. For the purposes of this invention, these plasma levels can now be achieved by oral administration of ectelida analogues of less than 2 gm, less than 1 gm, or less than 0.5 gm.

[0225] Co-application

[0226] Through the teachings of this article, those skilled in the art will readily recognize the value of combining analogues and compositions of the present invention with one or more second therapeutic agents.

[0227] Pumps of the P-gp and / or BCRP type are known to reduce the accumulation (or therapeutic exposure) of certain therapeutic agents (e.g., therapeutic agents as pump substrates) in pump-protected target tissues while exceeding tolerable exposure in non-pump-protected non-target tissues. Non-limiting examples of such targets are the brain and solid tumors. Therefore, analogues and compositions of the present invention are useful when co-administered with one or more such therapeutic agents.

[0228] Examples of therapeutic agents that can be used in combination with analogues or compositions of the present invention are tyrosine kinase inhibitors, such as, for example, dasatinib, gefitinib, imatinib, pazopanib, sorafenib, sunitinib, erlotinib, and vandetanib.

[0229] Other examples of therapeutic agents that can be used in combination with analogues or compositions of the present invention are other antitumor agents, such as, for example, crizotinib, docetaxel, doxorubicin, imidazotrazine, ispinax, paclitaxel, tazestat, temozolomide, and topotecan.

[0230] Optionally, the second therapeutic agent is an antitumor drug. Examples of antitumor drugs include vinca alkaloids, anthracyclines, paclitaxel and its derivatives, podophyllotoxin, mitoxantrone, actinomycin, colchicine, bacitracin D, acridine, or any drug exhibiting cross-resistance with the aforementioned drugs and characterized by a so-called multidrug resistance (“MDR”) phenotype.

[0231] Other examples of therapeutic agents that can be used in combination with analogues or compositions of the present invention are antiviral and antiretroviral drugs, such as, for example, abacavir, ampravir, lamivudine, ritonavir, and zidovudine.

[0232] Other examples of therapeutic agents that can be used in combination with analogues or compositions of the present invention are opioid receptor agonists, such as, for example, loperamide, morphine, and n-desmethylloperamide.

[0233] In another embodiment, the present invention provides individual dosage forms of the ectolidar analogue of the present invention and one or more of the aforementioned second therapeutic agents or therapeutic agent classes, wherein the ectolidar analogue and the second therapeutic agent are associated with each other. As used herein, the term “associated with each other” includes individual dosage forms packaged together or otherwise attached to each other, such that it is readily apparent that the individual dosage forms are intended to be sold and administered together (continuously or simultaneously within 24 hours of each other).

[0234] According to the present invention, one or more therapeutic agents and ectolida analogues may be administered co-administered with a second, third, or fourth drug, such that all drugs are present simultaneously in the subject. For example, ectolida analogues may be administered before, after, or simultaneously with the second drug.

[0235] How to use

[0236] In one embodiment, the present invention provides a method comprising administering an eclida analogue of the present invention to a subject in need.

[0237] In another embodiment, the present invention provides a method for enhancing the efficacy of a therapeutic agent, the method comprising co-administering the ecrida analogue of the present invention and the therapeutic agent, wherein optionally the therapeutic agent is a substrate of a P-gp pump or a BCRP pump.

[0238] For example, the ecrida analogues of the present invention can be used to sensitize multidrug-resistant cancer cells to chemotherapeutic agents.

[0239] Optionally, the subject is a mammal or a human.

[0240] Optionally, the administration is oral or by injection.

[0241] Optionally, the eclida analogues of the present invention are administered in the form of pharmaceutically acceptable compositions taught herein.

[0242] Optionally, the method includes co-administering a second therapeutic agent, such as the second therapeutic agent taught herein.

[0243] Excellent and unexpected nature

[0244] It has long been recognized that the need to provide means of increasing the accumulation of drugs in certain pump-protected target tissues (such as sites in solid tumors and the central nervous system) or the distribution of drugs to said target tissues has not been met. Mechanisms for limiting such accumulation or distribution are well known, namely the presence of certain naturally occurring or upregulated (e.g., particularly in certain pathologies or induced by drug exposure) efflux pumps that pump such drugs away from desired targets. Based on the inventive idea, the analogues and compositions of the present invention have been found to now provide properties significantly superior to previously known pump inhibitors or previously used ectodiazole compounds and compositions. It is now possible to use the analogues and compositions of the present invention in a manner that increases the accumulation of therapeutic agents in pump-protected target regions or the distribution of therapeutic agents to said target regions.

[0245] Given the aforementioned unpredictability of the results obtained from the deuteration of the active pharmaceutical ingredient, it is quite surprising that the ectolida analogues of the present invention, compared to unsubstituted ectolida, can improve systemic exposure and pharmacodynamic profiles. The improved pharmacokinetics of the deuterated ectolida analogues can be demonstrated by any of the following: improved in vivo half-life, increased AUC and Cmax, reduced first-pass metabolism in the GI tract and liver, and reduced metabolism demonstrated in vivo or in vitro (e.g., in microsomal or supersomal assays). Compared to undeuterated ectolida, the deuterated ectolida analogues can improve the pharmacodynamics of co-administered therapeutic agents by increasing the exposure of the therapeutic agent in pump-protected tissues and improving treatment response.

[0246] Therefore, it is now possible to achieve and maintain therapeutic levels of the therapeutic agent in pump-protected tissues while simultaneously reducing the levels of the therapeutic agent in systemic circulation and non-pump-protected tissues, resulting in reduced toxicity and other adverse events. This is due to the ability to achieve therapeutic levels in target tissues when administering lower doses of the therapeutic agent (otherwise, its toxicity would be too great to use). To illustrate this point differently, some therapeutic agents do not have a therapeutic window. To achieve therapeutic levels in target tissues, it is necessary to administer a therapeutic agent with a toxicity level. Due to the superior properties of the ecrida analogues of the present invention, the therapeutic index is greatly improved.

[0247] In some embodiments, (when compared with similar doses, administrations, and compositions of unsubstituted ectodiazole) the analogues of the present invention can increase the serum half-life by 20% or more than 40%. Similarly, the AUC of the analogues of the present invention can increase by 20% or more than 40%. Similarly, when the analogues and compositions of the present invention are co-administered with a therapeutic agent that serves as a substrate for a P-gp or BCRP-like pump, the level of such a therapeutic agent in pump-protected tissues such as the brain or solid tumors can be increased by up to 20% or 40% or more.

[0248] For example, (when compared with similar doses, administrations, and co-administration of unsubstituted ectotriazine) when co-administered with analogues and compositions of the present invention, the following compounds may show a significant increase in brain levels: dasatinib, gefitinib, imatinib, pazopanib, sorafenib, sunitinib and vandetanib, crizotinib, docetaxel, doxorubicin, imidazotrazine, ispinax, paclitaxel, tazestat, temozolomide and topotecan, abacavir, ampravir, lamivudine, ritonavir, zidovudine, loperamide, morphine, and n-desmethylloperamide.

[0249] As discussed above, according to the inventors' ideas, certain ectoda metabolites have also been found to be the cause of the toxic effects of ectoda administration, and the analogues of the present invention should be safer and exhibit less toxicity.

[0250] Example

[0251] The examples below are intended to illustrate, not limit, the invention. Furthermore, the scientific discussion below of the basic mechanisms of data collection is not intended to limit the invention described herein.

[0252] Example 1: Synthesis of analogues and compositions of the present invention

[0253] This example illustrates a synthetic method for the preparation of ecridinium analogs and deuterated analogs based on the deuteration of starting compounds. Synthesis and analog coding reference. Figure 4 .

[0254] Step 1

[0255] Compound 1 (270.5 g, 1.618 mol), compound 2 (357.8 g, 1.78 mol, 1.1 eq.), K₂CO₃ (447 g, 3.236 mol, 2.0 eq.), Cu (20.6 g, 0.324 mol, 0.2 eq.), and ethanol (2.7 L) were charged into a 12 L three-necked flask, and the resulting mixture was heated to reflux under nitrogen for 1 hour. After monitoring the reaction progress by LC-MS, the reaction mixture was cooled to room temperature. Water (2.7 L) was added, and the mixture was filtered through a diatomaceous earth mat. The diatomaceous earth was washed with water (1.35 L), and the combined filtrate was adjusted to pH ~2 by adding concentrated HCl (~410 mL) over 15 minutes. The resulting suspension was stirred at 10°C for 1.5 hours, and the solid was filtered, washed with water (2.7 L), and dried in a vacuum oven at 45°C for 2 days to obtain compound 3 (465 g, ~100%) as a yellow solid.

[0256] Step 2

[0257] A suspension of compound 3 (498 g, 1.734 mol) in acetonitrile (4.0 L) was heated to reflux with stirring. POCl3 (355.5 mL, 3.814 mol, 2.2 eq.) was added dropwise to the suspension over 2 hours. The mixture was heated to reflux for 2.5 hours and then cooled to 30 °C. Water (3.0 L) was slowly added to the mixture, and the resulting thick slurry was heated to reflux for 1.5 hours. The slurry was cooled to 10 °C and filtered. The solid was washed with water (2 × 1.0 L) and acetonitrile (2 × 1.0 L) and dried overnight in a vacuum oven at 45 °C to give compound 4 (426 g, 91.3%) as a yellow solid.

[0258] Step 3:

[0259] Compound 5 (475 g, 2.065 mol), compound 6 (474.8 g, 2.065 mol), K₂CO₃ (314 g, 2.273 mol), KI (68.6 g, 0.413 mol), and DMF (2.5 L) were charged into a 12 L three-necked flask. The resulting mixture was heated to 70 °C and stirred for 2.5 h. After the reaction was confirmed to be complete by LC-MS, the mixture was cooled to 50 °C and methanol (620 mL) was added. The mixture was then cooled to 30 °C and water (4.75 L) was added. The resulting suspension was cooled to 10 °C and stirred for 1 h. The solid was filtered, washed with water (2 × 2.5 L), and air-dried for 2 days to give compound 7 (630 g, 89.1%) as a yellow solid.

[0260] Step 4

[0261] Pd / C (10%, 50% wet, 30 g) was added to a solution of compound 7 (630 g, 1.84 mol) in THF / ethanol (8 L, 1:1). The mixture was stirred at 15–20 °C under a hydrogen atmosphere (1 atm, balloon) for 4 hours. The reaction mixture was filtered through a diatomaceous earth pad, and the pad was washed with THF (1.0 L). The filtrate was concentrated to 3 volumes under vacuum, and hexane (4.0 L) was added. The resulting slurry was cooled to 0 °C and stirred for 1 hour. The solid was filtered, washed with hexane (2 × 500 mL), and air-dried overnight to give compound 8 (522 g, 90.8%) as a grayish-white solid.

[0262] Step 5

[0263] Compound 4 (250 g, 0.929 mol, 1 eq.), compound 8 (290 g, 0.929 mol, 1 eq.), and DMF (2.5 L) were charged into a 5 L three-necked flask, and the resulting mixture was stirred at room temperature until a clear solution was obtained. TBTU (328 g, 1.021 mol, 1.1 eq.) was added to the solution, followed by triethylamine (272 mL, 1.95 mol, 2.1 eq.), and the resulting mixture was stirred overnight at room temperature under nitrogen. The mixture was slowly poured into water (7.5 L) with stirring, and the resulting suspension was stirred at room temperature for 1 hour. The solid was filtered and washed with water (2 × 7 L). The resulting solid was dried in a vacuum oven at 50 °C for two days, yielding 509.0 g (97.3%) of compound 9 as a yellow solid.

[0264] Step 6

[0265] 300.0 g (0.532 mol) of compound 9 was suspended in acetic acid (1.2 L) and heated to 70 °C. The resulting solution was hot-filtered and heated again to 70 °C. Then, preheated ethanol (70 °C, 3.6 L) was added. Concentrated HCl (66.0 mL, 0.792 mol, 1.5 eq.) was added dropwise to this solution over 30 minutes. The resulting solution was stirred at 70 °C until crystallization began (approximately 20 minutes). The suspension was cooled to room temperature over 3 hours, filtered, washed with ethanol (2 × 1.8 L), and dried over a vacuum oven at 60 °C for an over-the-week period to give compound 10 (253.0 g, 79.2%) as a brown solid.

[0266] Example 2: Preparation of deuterated ecridinium analogue EE60.

[0267] EE60 is through Figure 4 As shown and as in Figure 5 It is synthesized through a continuous process.

[0268] The EE60 structure was confirmed as follows: 5 μl samples were measured using an LC system including an UltiMate 3000 LC system (Dionex, Sunnyvale, CA) and a 2996 UV diode array detector (Waters). Samples were injected into a 100 × 2 mm (ID) 3.5 μm ZORBAX Extend-C18 column (Agilent Technologies, Santa Clara, CA). Elution was performed using a 5-minute gradient from 20% to 95% B at a flow rate of 0.4 mL / min (mobile phase A was 0.1% HCOOH aqueous solution (v / v), and mobile phase B was methanol). 95% B was maintained for 1 minute, followed by reequilibration at 20% B. Chromeleon (v6.8) was used for data acquisition and peak processing.

[0269] Example 3: Preparation of deuterated ecridinium analogue EE59

[0270] EE59 is through Figure 6 The process shown is used for synthesis.

[0271] The resulting yellowish-brown precipitate was removed by filtration, and the filter cake was dried overnight (72 mg). LCMS analysis of the filter cake indicated the presence of single peaks at multiple wavelengths (215 nm, 220 nm, 254 nm, 280 nm); each peak confirmed the presence of the desired product (LC retention time, 5.3 min; m / z = 575 [(M+H)+]).

[0272] EE598 1 H NMR revealed 1 H NMR (400MHz, DMSO-d6) δ12.3(s,1H),10.6(s,1H),8.51-8.46(m,2H),7.80(d,J=8.8Hz,1H),7.66(d,J=7.6Hz,2H ),7.45-7.38(m,2H),7.32-7.25(m,3H),6.66(d,J=6.8Hz,2H),3.62(s,2H),2.86(t,J=6.8Hz,2H),2.66(m,4H).

[0273] Example 4: Demonstration of the superior properties of analogues and compositions of the present invention: in vivo ADMET.

[0274] Pharmacological studies were performed according to Ward KW et al. (2001 Xenobiotica 31:783-797) and Ward and Azzarano (Journal of Pharmacology and Experimental Therapy (JPET) 310:703–709, 2004). Briefly, analogues of the present invention are administered in solution in 10% polyethylene glycol 300 (PEG-300) or 6% Cavitron with 1% dimethyl sulfoxide, or in a well-milled suspension in 0.5% HPMC aqueous solution containing 1% Tween 80. Blood samples were collected at various times up to 48 hours after drug administration; plasma samples were prepared and stored at 70°C until analysis.

[0275] Mice. The analogues of the present invention were administered to four groups of animals via oral strong feed (10 ml / kg dose volume). Three groups received the analogues of the present invention in suspension form at 3 mg / kg, 30 mg / kg, or 300 mg / kg, and a fourth group received the analogues of the present invention in solution form in Cavitron at 3 mg / kg. Blood samples were taken from the mice via the tail vein at 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h, and 32 h post-administration.

[0276] Rats. A total of seven groups of animals received the analogues of the present invention via oral bolus feeding (10 ml / kg). Three groups received the analogues of the present invention in suspension form at 3 mg / kg, 30 mg / kg, or 300 mg / kg, and groups four and five each received the analogues of the present invention in solution form at 3 mg / kg in Cavitron or PEG-300. Rats in groups six and seven with indwelling portal vein catheters received the analogues of the present invention via oral bolus feeding (10 ml / kg) in suspension form at 3 mg / kg or 30 mg / kg, respectively. Blood sampling of rats was performed via the lateral tail vein; samples were also obtained from the portal vein catheter. Blood samples were obtained before administration and at 5, 15, 30, and 45 minutes, and at 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 24 hours, and 32 hours after administration.

[0277] Dogs received the analogue of the invention in suspension form via irrigation (4 ml / kg) at three separate times, and in solution form in Cavitron at a dose of 3 mg / kg. Blood samples were obtained from the cephalic vein and from the portal vein catheter before administration and at 5, 15, 30, and 45 minutes, and at 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 32, and 48 hours after administration.

[0278] Monkeys received the analogues of the invention in suspension form via oral bolus feeding (8 ml / kg dose volume) at three separate times, and in solution form in Cavitron at a dose of 3 mg / kg. Blood samples were obtained via indwelling catheters from the femoral vein and porta hepatis at 5, 15, and 30 minutes, and at 1, 1.5, 2, 4, 6, 8, 10, 24, 32, and 48 hours after administration.

[0279] Human healthy volunteers orally received analogues of the present invention at doses ranging from 25 mg to 1000 mg. Blood samples were obtained and analogue concentrations were analyzed at 0, 15, 30, 45, 60, 90, 120, 180, 2, 4, 6, 8, 12, 24, and 48 hours after administration.

[0280] Analytical methods

[0281] The analogues of the invention were separated from the sample by precipitation with acetonitrile and quantified by LC / MS / MS coupled to an atmospheric pressure chemical ionization interface (475°C). An internal standard [in acetonitrile / 10 mM ammonium formate, pH 3.0; 95:5 (v / v)] was added to 50 μl of the sample, and the mixture was vortexed and centrifuged at 4000 rpm for 30 min. The supernatant was injected into the LC / MS / MS system in focusing mode using an HTS PAL autosampler (CTC Analytics, Zwingen, Switzerland) coupled to an Aria TX2 high-throughput liquid chromatography system, employing turbulent flow technology (Cohesive Technologies, Franklin, MA) in focusing mode. The mobile phase consisted of a mixture of water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. The turbulent column was a 0.5 × 50-mm Cyclone P column (binder technique) connected in series with a 2 × 20 mm, 4 μm Polar RP (Phenomenex, Torrance, CA) analytical column. Positive ion multiple reaction monitoring was used to detect the analogs and internal standard of the present invention, with the selected precursor and product ions having m / z 564 and 252, respectively. Linear response of the analyte / internal standard peak area ratio was observed using (1 / x) weighted linear regression analysis of the calibration curves for concentrations of the analogs of the present invention ranging from 2 to 10,000 ng / mL.

[0282] Alternatively, a useful analytical method for demonstrating the surprising and superior properties of the eclida analogues of the present invention is the method described by Stokvis et al., Journal of Mass Spectrometry (J Mass Spectr) 2004:39:1122-1130.

[0283] Pharmacokinetic data analysis

[0284] Concentration-time curves for each analyte were obtained for each animal, and non-compartmental analyses were performed using WinNonlin Professional version 3.3 (Pharsight, Mountain View, CA) to recover the area under the curve (AUC), Cmax, and other parameters. Dose-normalized AUC (DNAUC) (min × kg / L) was determined by dividing the AUC by the dose (mg / kg) and then multiplying by 1000. For studies where both portal and systemic data were available, such as those described in (Ward et al., 2001 Drug Metabolism and Disposal 29:82–88) for estimated absorption and first-pass liver extraction, [further details are needed].

[0285] result

[0286] Significant species variability exists among mice, rats, dogs, monkeys, and humans. Nevertheless, based on the insights of the inventors, the analogues of the present invention, when compared with the same dose of (unsubstituted) ecstasy, possess one or more of the following superior properties: (1) increased AUC; (2) increased DNAUC; (3) decreased pre-systemic clearance; (4) increased Cmax; (5) increased Tmax; (6) increased half-life; and (7) increased absorption.

[0287] Example 5: Demonstration of the superior properties of analogues and compositions of the present invention: in vitro metabolism.

[0288] This study was designed to predict the biotransformation of ectenadine in a liver metabolism model and to compare it with analogues of the present invention. Furthermore, the effects of CYP450 inhibitors (such as ritonavir) on metabolic transformation were examined.

[0289] In one study, a human liver microsome system was used; the microsomes were obtained from a commercial source (Thermo Scientific). Additionally, liver microsomes were prepared from wild-type, Cyp3a knockout, and Cyp3a KO mice; and CYP3A4 transgenic mice.

[0290] Biotransformation of different concentrations of ecridia and analogues of the present invention were incubated with microsomes in an NADPH regeneration system, as described by Cheng et al. (Nature's Handbook of Experiments 2009; 4: 1258-1261) and Hendrikx et al. (International Journal of Cancer 2013; 132: 2439-2447).

[0291] The methods described in Example 2 or those used to monitor Ecrida and similar products of the present invention are as follows: liquid chromatography coupled with an ultraviolet photodiode array (LC-UV-PDA), fluorescence detection (FD), and LC mass spectrometry.

[0292] In vitro metabolic studies were conducted in the absence and presence of inhibitors, such as CYP3A4: ritonavir, ketoconazole; CYP3A4 / CYP2C19: fluconazole; CYP2C19 / CYP2A6: fluoxetine; CYP2C8: clopidogrel, to indirectly identify enzymes responsible for biotransformation.

[0293] result

[0294] Based on the insights of the inventors, the results will be as follows: when compared with the unsubstituted eclipta parent, the analogues of the present invention (e.g., especially EE49-EE60) will have one or more of the following superior properties: (1) an increased half-life of the analogue; (2) the appearance of one or more minor metabolites during incubation of the eclipta analogues of the present invention, but at a significantly reduced rate and abundance; and (3) the absence or near absence of certain metabolites present during incubation of eclipta samples in the eclipta analogue samples of the present invention. Results from incubation of the eclipta analogues in the presence of various CYP inhibitors indicate that biotransformation is a result of an enzymatic process, and that this process can be prevented or reduced by deuteration as taught herein.

[0295] Example 6: Demonstration of the superior properties of analogues and compositions of the present invention: promoting the accumulation / distribution of co-administered therapeutic agents to pump-protected target sites.

[0296] This example uses the co-administration of an analogue of the present invention (compared to unsubstituted ectelida) and erlotinib (a dual substrate of P-gp and BCRP). It is well known that the presence of P-gp and BCRP at the blood-brain barrier significantly limits the bioavailability of erlotinib in the brain. The ectelida analogue of the present invention and unsubstituted ectelida were administered to wild-type rats at a dose of 20 mg / kg po. Rats were pretreated with (1) the analogue of the present invention or (2) unsubstituted ectelida at various doses (e.g., 10 mg / kg). Plasma and brain concentrations of erlotinib were measured at various time points (e.g., 30 min, 1 h, 2 h, 4 h, 8 h, and 12 h after administration).

[0297] Through the inventors' insights, the analogues of the present invention (e.g., especially EE49-EE60) provide a significant increase in erlotinib brain concentrations when compared to similar administrations of unsubstituted ecstasy. Furthermore, the use of the analogues of the present invention also reduces toxicity when compared to unsubstituted ecstasy.

Claims

1. An analogue represented by Formula 1 or a pharmaceutically acceptable salt thereof: in Each Y and each W is independently selected from either hydrogen or deuterium; Each R is independently selected from CH3, CH2D1, CH1D2, and CD3. And among them, The similar items are selected from the group consisting of: (a) Y14 and Y15 are each composed of deuterium, and each of the remaining Y, W and R does not contain deuterium; (b) R2 and R3 are each composed of CD3, and each of the remaining Y, W and R does not contain deuterium; (c) R2 and R3 are each composed of CD3, and Y14 and Y15 are each composed of deuterium, and each of the remaining Y, W and R does not contain deuterium; (d) Y2 is deuterium, and each of the remaining Y, W and R does not contain deuterium; (e) Y2 is deuterium, and R2 and R3 are each composed of CD3, and each of the remaining Y, W and R does not contain deuterium; (f) R1 is CD3, and Y14 and Y15 are each composed of deuterium, and each of the remaining Y, W and R does not contain deuterium; (g) Y9 and Y18 are each composed of deuterium, and each of the remaining Y, W and R does not contain deuterium; (h) Y2, Y9, Y18, and W1-W4 are each composed of free deuterium, and R1-R3 are each composed of free CD3, wherein each of the remaining Y, W, and R does not contain deuterium; or (i) R1, R2 and R3 are each composed of CD3, and Y14 and Y15 are each composed of deuterium, and each of the remaining Y, W and R does not contain deuterium.

2. The analogue of claim 1, wherein when administered orally in humans, rats or mice at doses of 1 mg / kg, 5 mg / kg or 10 mg / kg, the AUC 0-∞ of the analogue is increased by at least 20% compared to unsubstituted ecrifa.

3. The analogue of claim 2, wherein the AUC 0-∞ is increased by at least 40%.

4. The analogue of claim 1, wherein when administered orally in humans, rats or mice at a dose of 1 mg / kg, 5 mg / kg or 10 mg / kg, the plasma half-life of the analogue is prolonged by at least 20% compared to unsubstituted ectoda.

5. The analogue of claim 4, wherein the plasma half-life is extended by at least 40%.

6. The analogue of claim 1, wherein when administered orally in humans, rats or mice at a dose of 1 mg / kg, 5 mg / kg or 10 mg / kg and co-administered orally with erlotinib at 20 mg / kg, the administration causes an increase of at least 20% in brain Kp of erlotinib.

7. The analogue of claim 6, wherein the brain Kp is increased by at least 40%.

8. A pharmaceutical composition comprising the analogue according to claim 1, wherein the isotopic purity of the analogue is greater than 80%.

9. A pharmaceutical composition comprising an analogue according to claim 1 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising an analogue according to claim 1 and one or more therapeutic agents.

11. Use of an analogue of any one of claims 1 to 7 in the preparation of a medicament for increasing the brain concentration of a therapeutic agent, wherein the therapeutic agent is erlotinib, and wherein the medicament is formulated for administration in combination with the therapeutic agent.

Citation Information

Patent Citations

  • Efflux inhibitor compositions and methods of treatment using the same

    US20140235631A1

  • Synthesis of acridine derivative multidrug-resistant inhibitors

    US6248891B1

  • Delivery of erectile dysfunction drugs through an inhalation route

    US6803031B2